This is a working overview of Insulin-like growth factor 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Research === Baeocystin (PLZ-1019) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Norpsilocin (PLZ-1017) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Roluperidone (CYR-101, MIN-101, MT-210) – serotonin 5-HT2A, sigma σ2, and α1A-adrenergic receptor antagonist Squalamine (ENT-01; Enterin-01; kenterin) – various actions
=== Other anabolic agents === Clenbuterol – a beta-agonist; anabolic ability dubious Selective androgen receptor modulators (SARMs) Tibolone – a synthetic steroid Zeranol – a nonsteroidal estrogen Zilpaterol – a beta2-agnoist; anabolic ability dubious
== Plot == In 1982, French President François Mitterrand launches an anonymous international competition to design a monumental building on the historic axis linking the Louvre and the Arc de Triomphe. To general surprise, the winning entry comes not from one of the world's major architectural firms but from Johan Otto von Spreckelsen, a 53-year-old architecture teacher from Copenhagen who is unknown in France and has previously built only a handful of structures, including his own house and three small chapels. Overnight, von Spreckelsen is put in charge of the largest building project of the era, the Grande Arche de la Défense, which he affectionately calls his "cube". Determined to see the structure built exactly as he first envisioned it, he clashes repeatedly with the realities of French bureaucracy, represented chiefly by project administrator Jean-Louis Subileau, and with the pragmatic French architect Paul Andreu, who is brought in to oversee the building's technical execution. His uncompromising attachment to his original design, including a marble cladding that proves both structurally troublesome and hugely expensive, increasingly isolates him from the project's engineers and financiers. When the 1986 legislative elections bring a new, right-wing government to power in cohabitation with Mitterrand, the political backing that had protected von Spreckelsen evaporates. The film ends on a bleak note: worn down by the years-long conflict, von Spreckelsen dies before the Grande Arche is completed, which is inaugurated two years later.
doi:10.1126/scitranslmed.aaf1059. PMC 5505565. PMID 27225182. Park, J; Wetzel, I; Marriott, I; Dréau, D; D'Avanzo, C; Kim, D-Y; Tanzi, RE; Cho, H (2018). "Neuron-Glia Interactions Recapitulated in a 3D Organotypic Human Alzheimer's Disease Brain Model". Nature Neuroscience. 21 (7): 941–951. doi:10.1038/s41593-018-0175-4. PMC 6800152. PMID 29950669. Eimer, WA; Kumar, D; Kumar, N; Breakefield, XO; Tanzi, RE; Moir, RD (2018). "Alzheimer's Disease-Associated b-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection". Neuron. 99 (1): 1–9. doi:10.1016/j.neuron.2018.06.030. PMC 6075814. PMID 30001512.
== Effects of lack of CCAP == There have been no mutant individuals of any species found to possess CCAP who have a genetic defect meaning they are not able to produce the peptide. It is likely any such mutation would be lethal. In Drosophila the destruction of CCAP-containing neurons during development causes major changes in and disruptions to timing and behaviour of moulting.
Sources: en.wikipedia.org
ISBN 978-1-119-54212-4. OCLC 1083261548. Stvrtinová V, Jakubovský J, Hulín I (1995). Pathophysiology: Principles of Disease. Computing Centre, Slovak Academy of Sciences: Academic Electronic Press. Swartz, Mark H. (2010). Textbook of Physical Diagnosis: History and Examination (6th ed.). Saunders/Elsevier. ISBN 978-1-4160-6203-5. Concise Oxford Companion to the English Language 1998 entries on classical compound and combining form Taber, Clarence Wilbur; Thomas, Clayton L.; Venes, Donald (2001). Taber's cyclopedic medical dictionary (Ed. 19, illustrated in full color ed.). Philadelphia: F.A.Davis Co. ISBN 0-8036-0655-9. ISSN 1065-1357. Waquet, Françoise (2001). Latin, or the Empire of a Sign: From the Sixteenth to the Twentieth Centuries. Translated by John Howe. Verso. ISBN 1859844022.
=== Organic carbon === The removal of organic carbon from water is one of the differentiators between deionized water and ultrapure water. Sources include bacteria, leaching from plastic piping, and dissolved atmospheric sources. Organic carbon can be removed using filtration by activated carbon and oxidation of organic carbon to carbon dioxide/bicarbonate.
Between 1815 and 1824, the Rev William Buckland, the first Reader of Geology at the University of Oxford, collected more fossilized bones of Megalosaurus and became the first person to describe a non-avian dinosaur in a scientific journal. The second non-avian dinosaur genus to be identified, Iguanodon, was purportedly discovered in 1822 by Mary Ann Mantell, the wife of English geologist Gideon Mantell, though this is disputed and some historians say Gideon had acquired remains years earlier. Gideon Mantell recognized similarities between his fossils and the bones of modern iguanas and published his findings in 1825. The study of these "great fossil lizards" soon became of great interest to European and American scientists. Owen recognized that the remains that had been found so far, Iguanodon, Megalosaurus and Hylaeosaurus, shared distinctive features, and so decided to present them as a distinct taxonomic group. As clarified by British geologist and historian Hugh Torrens, Owen had given a presentation about fossil reptiles to the British Association for the Advancement of Science in 1841, but reports of the time show that Owen did not mention the word "dinosaur", nor recognize dinosaurs as a distinct group of reptiles in his address. He introduced the Dinosauria only in the revised text version of his talk published in April 1842. With the backing of Prince Albert, the husband of Queen Victoria, Owen established the Natural History Museum, London, to display the national collection of dinosaur fossils and other biological and geological exhibits.
Woods fled to England that year, where he campaigned against apartheid and further publicised Biko's life and death, writing many newspaper articles about him, as well as a book, Biko (1978). This was made into the 1987 film Cry Freedom by Richard Attenborough, starring Denzel Washington as Biko. Many film critics and Black Consciousness proponents were concerned that the film foregrounded white characters like Woods over Biko himself, but Cry Freedom brought Biko's life and activism to a wider audience. The state censors initially permitted its release in South Africa, but after it began screening in the country's cinemas, copies were confiscated by police on the order of Police Commissioner General Hendrik de Wit, who claimed that it would inflame tensions and endanger public safety. The South African government banned many books about Biko, including those of Arnold and Woods. In 2025, the National Prosecuting Authority announced it would re-open the inquest into Biko's death.
Worldwide about one billion people are estimated to be iodine-deficient; however, it is unknown how often this results in hypothyroidism. In the United States, overt hypothyroidism occurs in approximately 0.3–0.4% of people. Subclinical hypothyroidism, a milder form of hypothyroidism characterized by normal thyroxine levels and an elevated TSH level, is thought to occur in 4.3–8.5% of people in the United States. Hypothyroidism is more common in women than in men. People over the age of 60 are more commonly affected. Dogs are also known to develop hypothyroidism, as are cats and horses, albeit more rarely. The word hypothyroidism is from the Greek hypo- ('reduced'), thyreos ('shield'), and eidos ('form'), whereby the two latter parts refer to the thyroid gland.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.